title: Molecular targets of selenium in prostate cancer prevention (Review).
abstract: Prostate cancer is one of the leading causes of cancer-related deaths among males. Although use of the micro-nutrient selenium in prostate cancer clinical trials is limited, the outcomes indicate that selenium is a promising treatment. Furthermore, selenium inhibits prostate cancer through multiple mechanisms, and it is beneficial in controlling the development of this disease. This review highlights the latest epidemiological and biomolecular research on selenium in prostate cancer, as well as its prospects for future clinical use.
authors.affiliation: Division of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang Km.21, Jatinangor 45363, Indonesia. abdulahrizky@gmail.com
authors.forename: Rizky
authors.initials: R
authors.lastname: Abdulah
authors.forename: Kenji
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Chiho
authors.initials: C
authors.lastname: Yamazaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Koyama
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control; D012643:Selenium / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D012643:Selenium